Drug Database · Clinicians

Mefenamic acid + Tranexamic acid

Brands (1) TranamicShow all

Anti-fibrinolytic/Non-Steroidal anti-inflammatory drug (NSAID) PH FDA category
Fixed-dose combination.

Rx · Prescription drug1 PH product
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

  • Use: For management of mild to moderate pain in patient 14 years of age and older, when therapy will not exceed one week (7 days). US FDA label

    Kidney dosing: Mefenamic acid (single-agent)
    Show full dosing details
    CrCl ≥60 mL/min
    500 mg first dose, then 250 mg every 6 hours as needed; usually not beyond 1 week (label). Check kidney function before use if risk factors.
    CrCl 30–59 mL/min
    Label 8.6: should not be given to patients with pre-existing kidney disease or significantly impaired kidney function; metabolites (excreted mainly in urine) may accumulate. Not studied in kidney impairment.
    CrCl 15–29 mL/min
    Label 8.6: should not be given to patients with pre-existing kidney disease or significantly impaired kidney function; metabolites (excreted mainly in urine) may accumulate. Not studied in kidney impairment.
    CrCl <15 mL/min (not on dialysis)
    Label 8.6: should not be given to patients with pre-existing kidney disease or significantly impaired kidney function; metabolites (excreted mainly in urine) may accumulate. Not studied in kidney impairment.
    Hemodialysis (intermittent)
    Avoid (label: not in pre-existing kidney disease). Not dialyzable (high protein binding). NSAIDs may hasten loss of residual kidney function.
    Peritoneal dialysis
    Avoid (label: not in pre-existing kidney disease). NSAIDs may hasten loss of residual kidney function.
    CRRT
    Avoid: NSAIDs can worsen acute kidney injury.
    • Dialyzable? Unlikely: hemodialysis may not be useful because of high protein binding (label 10).
    • Monitoring Kidney function before and during use in at-risk patients; stop if kidney function worsens. Potassium, blood pressure; gastrointestinal bleeding.

    From the Mefenamic acid monograph (renalcarematters.com, reviewed).

  • Use: CYKLOKAPRON ® is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. US FDA label

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney dosing for each component (single-agent) is shown under Component information.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Film-coated tablet: 500 mg/250 mg

Registered products in the Philippines

1 product registered with the Food and Drug Administration (FDA) Philippines list Mefenamic acid + Tranexamic acid as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Mefenamic acid + Tranexamic acid
Package insert
TranamicTranexamic Acid+ Mefenamic Acid
500 mg/250 mg Film-Coated TabletAluminum Foil Strip x 6's (Box of 30's and 60's)
Rx
Concept Pharmaceuticals Ltd.India
Medethix, Inc.
DRP-10049
Dec 2, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .